0001179110-14-009095.txt : 20140523
0001179110-14-009095.hdr.sgml : 20140523
20140523194412
ACCESSION NUMBER: 0001179110-14-009095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140521
FILED AS OF DATE: 20140523
DATE AS OF CHANGE: 20140523
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
BUSINESS PHONE: 508-975-4820
MAIL ADDRESS:
STREET 1: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAKIANATHAN DEEPIKA
CENTRAL INDEX KEY: 0001270734
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 14868291
MAIL ADDRESS:
STREET 1: 3000 SAND HILL RD, BLDG 1, STE 135
STREET 2: C/O DELPHI VENTURES
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
edgar.xml
FORM 4 -
X0306
4
2014-05-21
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001270734
PAKIANATHAN DEEPIKA
DELPHI VENTURES, 3000 SAND HILL RD,
BLDG 1, STE 135
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2014-05-21
4
P
0
91754
26.194
A
2174550
I
By Delphi Ventures VIII, L.P.
Common Stock
2014-05-21
4
P
0
896
26.194
A
21233
I
By Delphi BioInvestments VIII, L.P.
Common Stock
2014-05-22
4
P
0
19807
26.0902
A
2194357
I
By Delphi Ventures VIII, L.P.
Common Stock
2014-05-22
4
P
0
193
26.0902
A
21426
I
By Delphi BioInvestments VIII, L.P.
Common Stock
2014-05-23
4
P
0
1752
26.4466
A
2196109
I
By Delphi Ventures VIII, L.P.
Common Stock
2014-05-23
4
P
0
17
26.4466
A
21443
I
By Delphi BioInvestments VIII, L.P.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.92 to $26.25, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.98 to $26.25, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.41 to $26.45, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
/s/ Matthew T. Potter, Attorney-in-Fact for Deepika R. Pakianathan
2014-05-23